Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

3.560 +0.050 (+1.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup
Via Investor Brand Network
Topics Intellectual Property
News headline image
$7.8 Million in New Financing for Clinic Acquisitions Supporting Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression and PTSD: NRXP
Via Get News
Topics Intellectual Property
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy
Via Investor Brand Network
News headline image
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion ↗
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
PsychedelicNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement
Via Investor Brand Network
Topics Intellectual Property
News headline image
Uncovering Potential: NRX Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Intellectual Property
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute
Via Investor Brand Network
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q1 2025 Results on May 15
Via Investor Brand Network
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
Via Investor Brand Network
Topics Intellectual Property
News headline image
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter ↗
Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11,... 
Via Stocktwits
Topics Intellectual Property Law Enforcement Lawsuit
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100
Via Investor Brand Network
News headline image
$4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Promising Treatment Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP
Via Get News
News headline image
$300 Million in Milestones; Double-Digit Royalties; LOI with Neurospa for Expansion of International Psychiatry Clinics; NDA Filed with FDA on New Drug: NRx Pharmaceuticals: (Stock Symbol: NRXP)
Via Get News
News headline image
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
News headline image
What's Going On With NRX Pharmaceuticals Stock Tuesday? ↗
NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics. 
Via Benzinga
News headline image
Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP
Via Get News
News headline image
What's Going On With NRX Pharmaceuticals Stock Thursday? ↗
NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute. 
Via Benzinga
News headline image
Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading. 
Via Benzinga
News headline image
New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Via Get News
Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20
Via Investor Brand Network
Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance Retirement
News headline image
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to... 
Via PRLog
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.